ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1792

Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE

Yevgeniya Gartshteyn1, Roberta Vezza Alexander2, John Conklin3, Thierry Dervieux4 and Anca Askanase5, 1Columbia University College of Physicians and Surgeons, Glen Rock, NJ, 2Exagen Inc, Vista, CA, 3Exagen Inc., Vista, CA, 4Prometheus Biosciences Inc, San Diego, CA, 5Columbia University College of Physicians and Surgeons, New York, NY

Meeting: ACR Convergence 2020

Keywords: antiphospholipid syndrome, Biomarkers, Cardiovascular, complement, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster III: Bench to Bedside

Session Type: Poster Session D

Session Time: 9:00AM-11:00AM

Background/Purpose: Platelet-bound complement activation products (PC4d), defined as PC4d20 net mean fluorescent intensity [MFI], or a thrombotic risk score that includes PC4d, C3 and anti-phosphatidylserine/prothrombin antibodies (anti-PS/PT IgG) (1) correlate with venous thromboses in SLE. The current study was initiated to further evaluate the association between PC4d and arterial and venous thrombotic events.

Methods: Using a cross-sectional design, we examined the association of PC4d, measured by flow cytometry, with thrombosis. PC4d was dichotomized and we evaluated the ability of different cutoff values, ranging from 5 to 20 net MFI, to discriminate for the history of vascular events. The thrombotic risk was calculated as previously described (1).

Results: 150 SLE patients (40 ±13 years old, 91% female, 33% Hispanic, 26% African American) were included; 38% had antiphospholipid antibodies (aPL). Thirty-one vascular events (18 venous, 13 arterial) occurred within five years of study enrollment. Arterial and venous events, as compared to no events, were associated with higher PC4d levels (median [IQR] 13.6 [4.4-24.0] and 13.2 [3.2-22.3] vs. 4.0 [2.5-8.3] net MFI, respectively, p< 0.05).  In a multivariable model adjusting for all significant co-variates identified in the univariable analysis (aPL, smoking, antimalarial use and prednisone >7.5mg/day), the association between all vascular events and PC4d (natural log transformed) remained significant (OR 1.7 95%CI 1.2-2.5, p=0.005).

The optimal PC4d cut-off point for vascular thromboses was identified to be 10 net MFI, with a sensitivity and specificity for venous events of 56% and 78%, and for arterial 62% and 78% (Table 1); PC4d≥10 net MFI, as compared to PC4d≥20 net MFI, resulted in a greater detection of individuals with vascular events (16/28 vs 11/28 respectively). Stratifying by aPL status, PC4d10 was associated with a history of any vascular event, with a stronger association seen in patients positive for both aPL and PC4d – OR 4.6 95% CI 1.3-16.9 for PC4d+/aPL- and OR 13.0 95% CI 3.7-46.0 for PC4d+/aPL+ as compared with PC4d-/aPL- patients (Figure 1).  A thrombotic score ≥ 2 (calculated using PC4d≥10) was associated with all events (arterial and venous) – OR 3.15 [95% CI 1.21, 8.19] and with arterial thrombosis – OR 4.44 [95% CI 1.24, 15.91] (Table 2).

Conclusion: PC4d and the thrombotic score associate with thrombotic events in SLE. The 10 net MFI PC4d cutoff was optimal for identifying patients with thromboses, and more specifically arterial events. PC4d10 could function more effectively as a biomarker of cardiovascular events, providing a novel risk indicator independent of aPL antibodies.

Table 1: Sensitivity and specificity of different PC4d cutoff levels for history of venous and arterial vascular events.

Table 2. Sensitivity, specificity, and odds ratio (OR) with 95% confidence intervals [95% CI] are reported for thrombotic score ≥ 2. The thrombotic score was calculated using cutoff for PC4d of 10 MFI. CVA: cardiovascular accidents, DVT: deep vein thrombosis, MI: myocardial infarction, NaN: not a number.

Figure 1: Vascular Events in SLE Stratified by Antiphospholipid Antibody (aPL) status and PC4d. Percent patients with a history of a vascular event within five years of study enrollment, stratified by aPL presence (NEG=negative; POS=positive) and PC4d status (NEG=PC4d 0.05.


Disclosure: Y. Gartshteyn, None; R. Alexander, Exagen Inc, 1; J. Conklin, Exagen, 1, 2; T. Dervieux, Exagen, 6; A. Askanase, GlaxoSmithKline, 2, 5, AstraZeneca, 2, 5, AbbVie, 5, Bristol Myers Squibb, 5, Janssen, 2, Eli Lilly, 2, Pfizer, 2, LuCIN, 2, Mallinckrodt Pharmaceuticals, 2.

To cite this abstract in AMA style:

Gartshteyn Y, Alexander R, Conklin J, Dervieux T, Askanase A. Platelet-bound C4d Is Associated with an Increased Risk of Arterial and Venous Thromboses in SLE [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/platelet-bound-c4d-is-associated-with-an-increased-risk-of-arterial-and-venous-thromboses-in-sle/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/platelet-bound-c4d-is-associated-with-an-increased-risk-of-arterial-and-venous-thromboses-in-sle/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology